deamidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | RP-HPLC, 214 nm | Wavelength affects relative peak areas |
| Identity confirmation | LC-MS/MS | Precursor and fragment ion masses compared |
| Common degradation | Deamidation, oxidation | Amide and methionine residues are main sites |
| Working solution storage | 2-8 °C, short term | Longer holding favours frozen aliquots |
| Adsorption risk | Higher below 1 mg/mL | Glass and plastic surfaces both affected |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Crude oil varies greatly in appearance depending on its composition. It is usually black or dark brown (although it may be yellowish, reddish, or even greenish). In the reservoir it is usually found in association with natural gas (which being lighter forms a "gas cap" over the petroleum) and saline water (which being heavier than most forms of crude oil, generally sinks beneath it). Crude oil may also be found in a semi-solid form mixed with sand and water, as in the Athabasca oil sands in Canada, where it is usually referred to as crude bitumen. In Canada, bitumen is considered a sticky, black, tar-like form of crude oil which is so thick and heavy that it must be heated or diluted before it will flow. Venezuela also has large amounts of oil in the Orinoco oil sands, although the hydrocarbons trapped in them are less viscous than in Canada and are usually called extra heavy oil. Oil sands resources are called unconventional oil to distinguish them from oil which can be extracted using traditional oil well methods. Between them, Canada and Venezuela contain an estimated 3.6 trillion barrels (570×10^9 m3) of bitumen and extra heavy oil, about twice the volume of the world's reserves of conventional oil.
=== Former commissioners === David Gallop was the initial chief executive officer of the restructured ARL Commission. He was previously the CEO of the NRL and his contract extension to become inaugural ARL CEO was a condition placed by News Limited with the ARL. On 5 June 2012 the ARL announced Gallop's departure from the CEO position and that he would take up a position at the FFA in 2013. David Smith was announced as the new ARL CEO in November 2012, taking charge on 1 February 2013.
I do almost all of my music work out of my studio at home. Ok, here goes: I use a pair of Adats, a Soundcraft Ghost for mixing, a bunch of outboard Symetrix and Lexicon processors for dynamics and effects, and an Eventide Ultraharmonizer DSP4000 for pre/post processing and vocal effects. For keyboards I use a mix of older and newer stuff. I have an old Prophet 5, a Casio FZ-1, a Roland MKS-50 with a programmer and an Oberheim Matrix 6. For newer gear, the Roland JP-8000, MC303, and the Novation Bass Station are nice for creating new sounds quickly. I also have a little Korg 05/wR with a software programmer that can be coaxed into making some fat sounds (no analog filter tho). I'm pretty religious about not using presets, so I really favor the more programmable synths. A lot of the recording and arrangement happens inside a PC; I run Logic Audio 2.5 for digital recording, post-processing and midi arrangement. I use an Audiomedia III card for digital transfers to and from a Tascam DA-30 dat. For guitar I use my trusty Les Paul through a Marshall half-stack, with an Oberheim Echoplex on the fx loop.
Sources: en.wikipedia.org
Antimicrobial activity – Citropten may exhibit antibacterial and antifungal properties. This characteristic could be relevant for applications in disinfectants or preservatives. Anti-inflammatory and antioxidant effects – Emerging research indicates citropten might have anti-inflammatory and antioxidant capabilities. These properties could hold promise for various health applications. The pleasant aroma of citropten makes it a valuable component in the fragrance industry, used in perfumes and cosmetics. Its potential antimicrobial properties are also prompting exploration for use in medicine and pharmaceuticals.
Liquid and solid carbon dioxide are important refrigerants, especially in the food industry, where they are employed during the transportation and storage of ice cream and other frozen foods. Solid carbon dioxide is called "dry ice" and is used for small shipments where refrigeration equipment is not practical. Solid carbon dioxide is always below −78.5 °C (−109.3 °F) at regular atmospheric pressure, regardless of the air temperature. Liquid carbon dioxide (industry nomenclature R744 or R-744) was used as a refrigerant prior to the use of dichlorodifluoromethane (R12, a chlorofluorocarbon (CFC) compound). CO2 might enjoy a renaissance because one of the main substitutes to CFCs, 1,1,1,2-tetrafluoroethane (R134a, a hydrofluorocarbon (HFC) compound) contributes to climate change more than CO2 does. CO2 physical properties are highly favorable for cooling, refrigeration, and heating purposes, having a high volumetric cooling capacity. Due to the need to operate at pressures of up to 130 bars (1,900 psi; 13,000 kPa), CO2 systems require highly mechanically resistant reservoirs and components that have already been developed for mass production in many sectors. In automobile air conditioning, in more than 90% of all driving conditions for latitudes higher than 50°, CO2 (R744) operates more efficiently than systems using HFCs (e.g., R134a). Its environmental advantages (GWP of 1, non-ozone depleting, non-toxic, non-flammable) could make it the future working fluid to replace current HFCs in cars, supermarkets, and heat pump water heaters, among others.
An independent body (a review board or a committee, institutional, regional, national, or supranational), constituted of medical/scientific professionals and nonmedical/nonscientific members, whose responsibility it is to ensure the protection of the rights, safety, and well-being of human subjects involved in a trial and to provide public assurance of that protection, by, among other things, reviewing and approving/providing favorable opinion on the trial protocol, the suitability of the investigator(s), facilities, and the methods and material to be used in obtaining and documenting informed consent of the trial subjects. The legal status, composition, function, operations, and regulatory requirements pertaining to Independent Ethics Committees may differ among countries, but should allow the Independent Ethics Committee to act in agreement with GCP as described in this guidance. (ICH E6) Indication
Kripke explained that Soldier Boy was Vought's version of Wayne since he worked for them for several decades and is someone who comes from a different era, but still has the ego and ambition for which he described him as the "Homelander before Homelander." Many of the changes were applied to give Homelander a threat just as he is finally starting to take control of Vought, but Kripke wanted to ensure that it was someone that the character has never faced before with someone that has the same strength as him and could actually fight him, for which he considered Soldier Boy to be the best match. Besides introducing Soldier Boy, the season also introduces the superhero team Payback for which the character was leader. Unlike in the comics where the team served as a rival of the Seven, Payback has already disbanded by the time where the series take place; it used to be the world's premiere team of supes before the Seven was formed and is described as "the Seven before the Seven." Kripke explained that the changes were mostly done to get a deeper exploration of Vought's history by exploring the past of each member of the teams, so the writers are allowed to shed light on the show's present. The season also includes a storyline focused mostly on Kimiko Miyashiro. As the season progresses, Kimiko goes through an emotional arc for which she starts learning to express herself after spending most of her life doing what other people wanted.
Sources: en.wikipedia.org
=== Pre-release === On April 12, 2000, Valve Software announced a partnership with the Counter-Strike Team, confirming that Counter-Strike 1.0 would be included in an upcoming Half-Life patch. Though not explicitly stated, it is widely believed that this followed Valve's acquisition of Counter-Strike. Statements suggest the rights were sold in early 2000, involving a financial transaction. Despite the partnership, two more beta versions were released. Beta 6.5 (June 8, 2000) introduced an updated netcode, while Beta 7.0 (August 26, 2000) added drive-able vehicles. Following the acquisition of the game by Valve, while Cliffe continued working for them, Le did additional work towards a Counter-Strike 2.0 based on Valve's upcoming Source engine, but left to start his own studio after Valve opted to shelve the sequel. Valve planned to release Counter-Strike both as a Half-Life mod and a standalone retail product on August 31, 2000. The decision aimed to increase accessibility and test market demand for a multiplayer game independent of Half-Life. Legal issues arose before the retail release, particularly regarding weapon names, which were changed to fictional alternatives. Valve also had to secure rights for maps and textures, leading to modifications and removals of certain assets. Minh Le, one of the original developers, compensated mappers whose work Valve did not purchase.
Biological differences in fractionation stem not only from biochemical differences between different molecules, but also from physiological differences between different organisms. For example, the δDs of multiple leaf wax molecules are enriched in shrubs (median ~ −90‰) relative to trees (median ~ −135‰), which themselves are enriched relative to both C3 (median ~ −160‰) and C4 grasses (median ~ −140‰). Between individual species, substantial variation in δD has been documented. Other physiological factors that contribute to variable leaf wax δD values include the seasonal timing of leaf development, response to external stress or environmental variability, and the presence or absence of stomata It can be difficult to distinguish between physiological factors and environmental factors, when many physiological adaptations are directly related to environment. Several environmental factors have been shown to contribute to leaf wax δD variability, in addition to environmental effects on the δD of source water. Humidity is known to impact lipid δD at moderate humidity levels, but not at particularly high (>80%) or low (<40%) humidity levels, and a broad trend of enriched δDs, meaning smaller εl/w, is seen in arid regions. Temperature and sunlight intensity, both correlated to latitude, have strong effects on the rates of metabolism and transpiration, and by extension on εl/w. Also, the average chain length of leaf wax molecules varies with geographic latitude, and εl/w has been shown to increase with increasing chain length.
=== Forms === Because of its chemical stability, pyridoxine hydrochloride is the form most commonly given as vitamin B6 dietary supplement. Absorbed pyridoxine (PN) is converted to pyridoxamine 5'-phosphate (PMP) by the enzyme pyridoxal kinase, with PMP further converted to pyridoxal 5'-phosphate (PLP), the metabolically active form, by the enzymes pyridoxamine-phosphate transaminase or pyridoxine 5'-phosphate oxidase, the latter of which also catalyzes the conversion of pyridoxine 5′-phosphate (PNP) to PLP. Pyridoxine 5'-phosphate oxidase is dependent on flavin mononucleotide (FMN) as a cofactor produced from riboflavin (vitamin B2). For degradation, in a non-reversible reaction, PLP is catabolized to 4-pyridoxic acid, which is excreted in urine.
Sources: en.wikipedia.org
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.
Peptides can bind to glass and plastic, so a fraction of the material leaves the solution. The effect is proportionally larger in dilute samples and can bias quantitative results.
Reverse-phase high-performance liquid chromatography is the most widely reported approach. Purity figures should always be quoted together with the wavelength, gradient, and integration parameters used.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.